ProfileGDS5678 / 1456224_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 67% 65% 65% 62% 64% 68% 68% 65% 64% 64% 64% 64% 66% 65% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.0916767
GSM967853U87-EV human glioblastoma xenograft - Control 23.8690265
GSM967854U87-EV human glioblastoma xenograft - Control 33.8687465
GSM967855U87-EV human glioblastoma xenograft - Control 43.6893762
GSM967856U87-EV human glioblastoma xenograft - Control 53.7960864
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1817468
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.2264368
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.8878765
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.8217264
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.842664
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8621964
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.8053564
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0188866
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.9073465